Long-Term Followup of Patients Treated With Total Lymphoid Irradiation for Lupus Nephritis
|
|
- Rudolph Evans
- 6 years ago
- Views:
Transcription
1 ARTHRITIS & RHEUMATISM Vol. 46, No. 4, April 2002, pp DOI /art , American College of Rheumatology Long-Term Followup of Patients Treated With Total Lymphoid Irradiation for Lupus Nephritis Mark C. Genovese, Zuzana Uhrin, Daniel A. Bloch, John Oehlert, Richard K. Sibley, Bryan Myers, and Samuel Strober Objective. To describe the long-term survival, renal condition, and morbidity outcomes in patients who received total lymphoid irradiation (TLI) for the treatment of lupus nephritis. Methods. Twenty-one patients with biopsy-proven, diffuse membranoproliferative glomerulonephritis and significant proteinuria of >2.5 grams/day received TLI from 1980 to 1987 at Stanford University Medical Center. All patients had previously failed to respond to treatment with high-dose corticosteroids or therapy with corticosteroids plus immunosuppressive agents (azathioprine, cyclophosphamide, or chlorambucil). Results. The mean duration of followup since TLI was 10.7 years. Fifteen of 21 patients (71%) remained alive at the time of this assessment. Nine of the 21 patients (43%) survived without developing end-stage renal disease (ESRD). The probability of long-term survival without ESRD and without need for additional immunosuppressive agents after TLI was 19% (4 of 21). Factors predicting renal failure at the time of TLI included elevated creatinine levels, increased interstitial fibrosis on renal biopsy, and increased fractional excretion of immunoglobulin and albumin. Malignancies were found in 4 patients, and opportunistic infections occurred in 7 patients. Conclusion. Overall, patients with lupus nephritis treated with TLI do not appear to have better 10-year survival with lower incidence of ESRD compared with Supported in part by grant AR from the NIH to ARAMIS. Mark C. Genovese, MD, Zuzana Uhrin, MD, Daniel A. Bloch, PhD, John Oehlert, PhD, Richard K. Sibley, MD, Bryan Myers, MD, Samuel Strober, MD: Stanford University Medical Center, Palo Alto, California. Address correspondence and reprint requests to Mark C. Genovese, MD, Stanford University Medical Center, Division of Immunology and Rheumatology, 1000 Welch Road, Suite 203, Palo Alto, CA genovese@leland.stanford.edu. Submitted for publication August 24, 2001; accepted in revised form December 5, patients in published series treated with conventional immunosuppressive therapies. However, in this series of patients, treatment with conventional immunosuppressive therapies had been unsuccessful and given the limited number of adverse events and the efficacy seen in some patients, TLI appears to be a reasonable therapeutic option for the treatment of severe lupus nephritis among patients who fail to respond under standard cytotoxic regimens. Total lymphoid irradiation (TLI) has been used extensively in the treatment of Hodgkin s lymphoma and it has also come into experimental use as an immunosuppressive therapy for various autoimmune conditions (1). TLI has been shown to induce long-term remission in several animal models of autoimmune disease, including adjuvant arthritis in rats and lupus-like disease in NZB/NZW mice (1). There are published reports of experience in using TLI in the treatment of rheumatoid arthritis (RA) (1 3), multiple sclerosis (4), and systemic lupus erythematosus (SLE) (1,3,5 9). TLI has also been studied as an alternative agent to cytotoxic drug therapy for patients with refractory lupus nephritis (1,3,5 9). Currently, there is extensive evidence supporting the efficacy of corticosteroids and cyclophosphamide and growing evidence for mycophenolate mofetil in the treatment of diffuse proliferative lupus nephritis (10 13), but there still remain those patients whose disease is refractory to the standard therapies and for whom alternative treatments may need to be considered. Previous studies of TLI as a treatment for intractable lupus nephritis have shown improvement, on average, in the extent of renal disease and in the serologic parameters of disease activity (proteinuria, serum levels of albumin, serum levels of anti double-stranded DNA antibodies) within 3 months of therapy, which persisted for at least 3 years (3,6,7). Although there was a significant reduction in the number and function of T 1014
2 TLI FOR THE TREATMENT OF LUPUS NEPHRITIS 1015 helper cells, recovery of these parameters was not associated with recurrence of disease activity. Overall, the risks of malignancy, infection, and sterility appear to be lower than with alkylating agents (6). However, one study demonstrated that TLI in the treatment of lupus nephritis had unfavorable outcomes, primarily related to infectious complications (9). The objective of this study was to review the long-term outcomes in 21 patients with biopsy-proven, diffuse proliferative lupus nephritis and severe proteinuria who received TLI after failing treatment with corticosteroids alone or in combination with cytotoxic agents. Many of these patients have been described in earlier reports (3,5 8). The main outcomes of this study were overall survival, renal survival, and morbidities such as development of severe infections and malignancies. PATIENTS AND METHODS The patients studied comprised those who received TLI for lupus nephritis at Stanford University Medical Center between 1980 and To receive treatment with TLI, patients were required to meet the American College of Rheumatology diagnostic criteria for SLE (14), to have recent ( 6 months) histopathologic evidence of lupus nephritis involving 85% of glomeruli, to have significant proteinuria ( 2.5 grams/day of protein), and to have a history of failure to respond to prednisone therapy or prednisone with immunosuppressive agents for 3 months. Exclusion criteria for original treatment with TLI included severe leukopenia, thrombocytopenia, or anemia. Patients were also excluded if they were 18 years of age, had received 6 months of treatment with alkylating agents during the previous 3 years, had chronic or acute infections, or had end-stage renal disease (ESRD) (serum creatinine 4 mg/dl or creatinine clearance 20 ml/minute). TLI therapy was given as described in previously published protocols (3,5 8) and included irradiation of the supradiaphragmatic mantle field encompassing the cervical, axillary, infraclavicular, pulmonary hilar, mediastinal lymph nodes, and the thymus gland. This field was treated with 200 cgy/day, 5 days/week, for a total of 2,000 cgy. The subdiaphragmatic field was treated after completion of the mantle, with cgy/day for 4 days/week, to a total dose of 2,000 cgy. Cytotoxic drugs were discontinued prior to the initiation of TLI. Followup information was obtained on all 21 patients, and all were contacted by the principal investigator to ensure accuracy of medical records. All renal biopsy reports were re-read for this study to assess the activity and chronicity indices. Analysis of the primary outcome, which is characterization of the factors predictive of the hazard of death or dialysis, was performed using univariate analysis with a Cox proportional hazard model. Univariate factors evaluated as potential predictors of death or dialysis included sex, body surface area, age at time of TLI, duration of disease prior to Table 1. Baseline and followup characteristics of the total lymphoid irradiation (TLI) treated patient cohort* Characteristic Value Baseline No. of patients 21 Age at TLI, years Female, no. 16 Male, no. 5 No. previously treated with corticosteroids 21 No. previously treated with immunosuppressives 16 Duration of SLE, years Serum creatinine, gm/dl GFR by inulin clearance, ml/minute/1.73 m Serum albumin, gm/dl WBC count, cells/mm Renal biopsy activity index Renal biopsy chronicity index Systolic blood pressure, mm Hg Diastolic blood pressure, mm Hg Followup No. of patients 21 Duration of followup, years No. alive 15 No. dead 6 Time to death, years No. with ESRD requiring dialysis 9 Time to dialysis, years No. requiring additional corticosteroids 21 No. requiring additional immunosuppressive agents 13 No. alive without ESRD or need for 4 immunosuppressives * Except where otherwise indicated, values are the mean SD. SLE systemic lupus erythematosus; GFR glomerular filtration rate; WBC white blood cell; ESRD end-stage renal disease. Includes 3 of the 6 who died. TLI, prior use of chemotherapy, levels of serum albumin, levels of serum creatinine, inulin clearance, fractional excretion of albumin or of immunoglobulin, 24-hour urine protein loss, activity index, chronicity index, % of globally sclerosed glomeruli, % of segmentally sclerosed glomeruli, and % of fractional interstitial area on biopsy. RESULTS Table 1 summarizes the baseline and followup characteristics of the 21 patients studied. As noted, the majority of patients were young women. All patients had received prior treatment with corticosteroids and 76% had received prior treatment with immunosuppressive agents. No patients were lost to followup. The average duration of followup was 10.7 years. Six patients (29%) died during the followup period (3 of whom developed ESRD prior to their death), while 9 patients in total (43%) developed ESRD. All patients required additional corticosteroids and 62% required additional immunosuppressive therapy following TLI. Four patients
3 1016 GENOVESE ET AL Table 2. Morbidity and mortality data on the TLI-treated patient cohort (n 21)* Morbidity/mortality Value Infections Total with opportunistic infections 7 Herpes zoster 5 Esophageal candidiasis 1 Fungal sinusitis 1 Deaths due to infections 0 Malignancies Total with malignancies 4 Lymphoma 1 Transplant-related lymphoma 1 Thyroid carcinoma 1 Cervical carcinoma 1 Deaths due to malignancies 0 Patients receiving cytotoxics prior to TLI 3 Patients receiving cytotoxics after TLI 3 Death Total deaths 6 Male 2 Female 4 Time to death from time of TLI, mean SD years Causes of death Cardiac 3 Aortic aneurysm 1 Renal failure 1 Vasculitis 1 * Except where otherwise indicated, values are the no. of patients. See Table 1 for definitions. remained alive without developing ESRD and without requirement for additional immunosuppressive therapy. Table 2 shows the morbidity and mortality results in this patient cohort. As noted, 7 patients developed opportunistic infections, the majority of which were due to herpes zoster. No patients died as a result of infection. Malignancies occurred in 4 patients: 2 with lymphomas, 1 with thyroid carcinoma, and 1 with cervical carcinoma. All malignancies responded to treatment and none were fatal. Three of these 4 patients had received cytotoxic treatments prior to and after TLI. Six patients died during the followup period, with a mean duration of time from TLI to death of 6 years. Fifty percent of these deaths (3 patients) were due to cardiac causes. The remaining 3 deaths were due to aortic aneurysm, vasculitis, or renal failure. Table 3 shows the results of the univariate analysis for predictors of the hazard of death or dialysis in the 21 TLI-treated patients. Twelve patients (57%) met the primary outcome of death or dialysis. The univariate analysis suggests that small (milligram) increases in the fractional excretion of albumin and immunoglobulin, as well as small (percentage) increases in interstitial fibrosis on biopsy were the strongest predictors of death or dialysis. Fractional excretion is expressed as a ratio, based on the excretion of urine albumin:serum albumin divided by the excretion of urine inulin:serum inulin. Small changes in the leakiness of the glomeruli can lead to fold changes in the fractional excretion, suggesting that although the hazard ratios appeared small in this cohort, as greater quantities of protein (albumin and immunoglobulin) are lost, the hazard of death or dialysis increases significantly. Other predictors that approached significance were the glomerular filtration rate, serum creatinine level, and the prevalence of glomeruli that were globally sclerosed on biopsy. Table 3. Predictors of the hazard of death or dialysis in the TLI-treated cohort* Variable Hazard ratio 95% CI P Male sex Age at time of TLI (in years) Disease duration at time of TLI (in years) Prior use of immunosuppression Body surface area (in m 2 ) , Serum albumin (in gm/dl) hour urinary protein loss (in gm) Chronicity index Activity index % globally sclerosed glomeruli on biopsy % segmentally sclerosed glomeruli on biopsy GFR by inulin clearance (in ml/minute/1.73 m 2 ) Serum creatinine (in mg/dl) % fractional interstitial area on biopsy % fractional excretion of albumin % fractional excretion of IgG * 95% CI 95% confidence interval (see Table 1 for other definitions).
4 TLI FOR THE TREATMENT OF LUPUS NEPHRITIS 1017 DISCUSSION TLI has been used to treat a variety of autoimmune disorders such as RA, SLE, and multiple sclerosis, as well as solid organ allograft rejection (1,4). TLI induces long-lasting CD4 T lymphocyte depletion as well as reduced humoral and cell-mediated responses (1). Studies in RA have shown tolerability and initial clinical efficacy but potential short- and long-term risks (2). TLI has been used to treat SLE since the early 1980s, showing initial efficacy in the NZB/NZW mouse model for lupus (1), and later, in human studies, in suppressing the activity of lupus nephritis (1,3,5 9). However, the long-term safety and efficacy of TLI for the treatment of lupus nephritis has remained controversial. Reported complications of TLI treatment have included the development of opportunistic infections, particularly herpes zoster, as well as hematologic malignancies (2,9). Lupus nephritis varies in its severity and rate of progression, and is an important determinant of overall prognosis in patients with SLE. Over the last decade, advances in the treatment of lupus nephritis have led to improvements in renal survival, but there are still questions about therapeutic options in patients with disease that is refractory to standard therapies. A metaanalysis of clinical trials in lupus nephritis reported that a regimen of immunosuppressives in conjunction with oral prednisone was more effective than oral prednisone alone for reducing total mortality and the occurrence of ESRD (10). More recent studies have shown that monthly bolus therapy with methylprednisolone was less effective than cyclophosphamide in treating proliferative lupus nephritis. Efficacy was greater when the 2 therapies were used in combination (12). Recent evidence supports the efficacy of mycophenolate mofetil in treating proliferative lupus nephritis, and other novel therapies are also being investigated, including intensive induction regimens (fludarabine and cyclophosphamide), immunoablative cyclophosphamide with or without stem-cell rescue, and costimulatory blockade (13,15,16). Despite these potential advances in therapy, lupus nephritis continues to pose a therapeutic challenge when conventional treatment regimens are not effective. The first 10 of our patients to receive TLI for lupus nephritis were reported in 1985 (5). Each patient had severe proteinuria and their condition had been refractory to therapy with azathioprine and prednisone (5). TLI was noted to halt the decline in the glomerular filtration rate, to reduce proteinuria, and to improve serologic markers, including complement levels and anti double-stranded DNA antibodies. Side effects included gastrointestional distress, cytopenias, herpes zoster infections, and cellulitis. One patient died of cardiac arrhythmia. Subsequent followup by Strober et al suggested persistent improvement and reduction in steroid therapy in the same cohort of patients (6,7). Overall, the risks of sterility, hematologic malignancy, and infections appeared to be lower than with alkylating agents. Another group of investigators reported unfavorable results in 2 patients treated with TLI for lupus nephritis. One patient developed herpes zoster, gram-negative sepsis, and worsening renal function requiring dialysis; the second patient died from bronchopneumonia and progressive renal failure (9). However, because there have never been any controlled trials comparing TLI directly with conventional cytotoxic therapy, it is difficult to draw solid conclusions about the risks and benefits of TLI when compared with cytotoxic therapies. This present study of 21 patients treated with TLI at Stanford University Medical Center for severe lupus nephritis, refractory to prednisone with or without immunosuppressive therapy, is the largest cohort of patients reported to date. Our results reveal that during the 10-year followup, 15 of the 21 patients remained alive, the disease has not progressed to ESRD in 9 of these patients, and 4 patients no longer require additional immunosuppressive therapies other than low-dose steroids. Of the 6 deaths, 3 were due to cardiac causes, reflecting the known cardiovascular risks of SLE and the effects of prolonged glucocorticoid therapy, which is often used to treat it. Although 7 patients developed opportunistic infections and 4 developed malignancies, all responded to appropriate therapy and none died from these causes. The outcome parameter chosen for this study was death or dialysis. These end points were chosen because of the high mortality and dialysis rates of patients with lupus nephritis, particularly in those patients refractory to cytotoxic therapy. Dialysis was chosen as an outcome, rather than a doubling of the creatinine level, because ultimately, an important long-term goal of therapy is the avoidance of the total loss of renal function. The best predictors of death or dialysis appeared to be reduction in the glomerular filtration rate at baseline, prominent glomerulosclerosis and interstitial fibrosis on renal biopsy, and marked leakiness of the glomerular filtration barrier to proteins at baseline. Although all biopsy samples were scored for activity and chronicity, neither score had a statistically significant association with the outcome of death or dialysis. While traditionally the degree of scarring based on chronicity scores from a renal biopsy has been of use in predicting response to
5 1018 GENOVESE ET AL therapy, this was not the case in this study. Scarring, reflected as the percentage of interstitial fibrosis and percentage of globally sclerosed glomeruli, appeared to be more useful, but no more so than the noninvasive measures of glomerular function. Overall, the baseline assessments of the glomerular filtration rate and fractional excretion of proteins (albumin and immunoglobulin) proved to be the best predictors of death or dialysis. Noninvasive measures have been utilized in the past and were found to be of utility (17,18). We recognize that there are limitations in this study. There is no matching cohort, no adjustment for multiple statistical comparisons, and no multivariate modeling. The uniqueness of the cohort made it impossible to identify a comparable cohort of patients with refractory lupus nephritis by which to develop a matched control set. We have described a group of patients with severe and refractory lupus nephritis who received TLI in the 1980s. A number of patients had apparent longterm benefit from this therapy, and a small number of nonfatal opportunistic infections and malignancies occurred. On average, patients with lupus nephritis treated with TLI do not appear to have better 10-year survival with retention of renal function than do those in published series treated with conventional cytotoxic regimens. However, TLI remains a salvage therapy with potential long-term benefit but also potential risks for patients with lupus nephritis. Because of its potential risks, it should be reserved for those with the most refractory disease and used only after standard therapies have failed. ACKNOWLEDGMENT We thank Michael Ward for review of the manuscript and insightful input. REFERENCES 1. Helfgott SM. Total lymphoid irradiation. Rheum Dis Clin North Am 1989;15: Uhrin Z, Wang BWE, Matsuda Y, Strober S, Genovese MC. Treatment of rheumatoid arthritis with total lymphoid irradiation: long-term survival. Arthritis Rheum 2001;44: Tanay A, Schiffman G, Strober S. Effect of total lymphoid irradiation on levels of serum autoantibodies in systemic lupus erythematosus and in rheumatoid arthritis. Arthritis Rheum 1986; 29: Cook SD, Devereux C, Troiano R, Wolansky L, Guarnaccia J, Haffy B, et al. Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis. J Neurol Sci 1997;152: Strober S, Field E, Hoppe RT, Kotzin BL, Shemesh O, Engleman E, et al. Treatment of intractable lupus nephritis with total lymphoid irradiation. Ann Intern Med 1985;102: Strober S, Farinas MC, Field EH, Solovera JJ, Kiberd BA, Myers BD, et al. Treatment of lupus nephritis with total lymphoid irradiation: observations during a month followup. Arthritis Rheum 1988;31: Strober S, Farinas MC, Field EH, Solovera JJ, Kiberd BA, Myers BD, et al. Lupus nephritis after total lymphoid irradiation: persistent improvement and reduction of steroid therapy. Ann Intern Med 1987;107: Chagnac A, Kiberd BA, Farinas MC, Strober S, Sibley RK, Hoppe R, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989;84: Ben-Chetrit E, Gross DJ, Braverman A, Weshler Z, Fuks Z, Slavin S, et al. Total lymphoid irradiation in refractory systemic lupus erythematosus. Ann Intern Med 1986;105: Bansal VK, Beto JA. Treatment of lupus nephritis: a meta-analysis of clinical trials. Am J Kidney Dis 1997;29: Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34: Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, et al. Methyl-prednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996;125: Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al, for the Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000;343: Tan E, Cohen MA, Fries JF, Masi AT, McShane DJ, Rothfield N, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1995;25: Austin HA, Balow JE. Treatment of lupus nephritis. Semin Nephrol 2000;20: Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stemcell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129: Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45: Conlon PJ, Fischer CA, Levesque MC, Smith SR, St. Clair EW, Allen NB, et al. Clinical, biochemical, and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin Nephrol 1996;46:170 5.
Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Int Urol Nephrol (2013) 45:1301 1308 DOI 10.1007/s11255-012-0331-9 NEPHROLOGY - ORIGINAL PAPER Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis Prayong Vachvanichsanong
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationGuidance for Industry Lupus Nephritis Caused By Systemic Lupus Erythematosus Developing Medical Products for Treatment
Guidance for Industry Lupus Nephritis Caused By Systemic Lupus Erythematosus Developing Medical Products for Treatment U.S. Department of Health and Human Services Food and Drug Administration Center for
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Idiopathic membranous nephropathy: use of other therapies GUIDELINES
Idiopathic membranous nephropathy: use of other therapies Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendations possible based on Level I or II evidence
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 20 Jun 2018 01:15:28 GMT) CTRI Number Last Modified On 29/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of steroid therapy GUIDELINES
Specific management of IgA nephropathy: role of steroid therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Steroid therapy may protect against progressive
More informationApproach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis
GLOMERULONEPHRITIDES Vivette D Agati Jai Radhakrishnan Approach to Glomerular Diseases: Clinical Presentation Nephrotic Syndrome Nephritis Heavy Proteinuria Renal failure Low serum Albumin Hypertension
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationRecurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab
TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3
More informationN. Hiramatsu, T. Kuroiwa, H. Ikeuchi, A. Maeshima, Y. Kaneko, K. Hiromura, K. Ueki and Y. Nojima
Rheumatology 28;47:72 77 Advance Access publication 4 April 28 doi:1.193/rheumatology/ken19 Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion
More informationLong-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide
The American Journal of Medicine (2006) 119, 355.e25-355.e33 CLINICAL RESEARCH STUDY Long-term Outcome of Diffuse Proliferative Lupus Glomerulonephritis Treated with Cyclophosphamide Chi Chiu Mok, MD,
More informationSwitching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes
Arthritis Care & Research Vol. 66, No. 12, December 2014, pp 1905 1909 DOI 10.1002/acr.22364 2014, American College of Rheumatology ORIGINAL ARTICLE Switching Treatment Between Mycophenolate Mofetil and
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationCommittee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationClinical Study Glomerulonephritis with Crescents in Children: Etiology and Predictors of Renal Outcome
International Scholarly Research Network ISRN Pediatrics Volume 2011, Article ID 507298, 5 pages doi:10.5402/2011/507298 Clinical Study Glomerulonephritis with Crescents in Children: Etiology and Predictors
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationEFFECT OF TOTAL LYMPHOID IRRADIATION ON LEVELS OF SERUM AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND IN RHEUMATOID ARTHRITIS
26 EFFECT OF TOTAL LYMPHOID IRRADIATION ON LEVELS OF SERUM AUTOANTIBODIES IN SYSTEMIC LUPUS ERYTHEMATOSUS AND IN RHEUMATOID ARTHRITIS AMIR TANAY, GERALD SCHIFFMAN, and SAMUEL STROBER The effects of total
More informationHigh Impact Rheumatology
High Impact Rheumatology Systemic Lupus Erythematosus Bernard Rubin, DO MPH Case 1: History A 45-year-old woman presents with severe dyspnea and cough. She was in excellent health until 4 weeks ago when
More informationMycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Michael Walsh,* Matthew James,* David Jayne, Marcello Tonelli, Braden J. Manns,* and Brenda R. Hemmelgarn*
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationUse of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome
Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent
More informationDisorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.
Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome. Azotemia and Urinary Abnormalities Disturbances in urine volume oliguria, anuria, polyuria Abnormalities of urine sediment red
More informationIdentification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
To cite: Dall Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science
More informationChapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org chapter 6 & 2012 KDIGO Chapter 6: Idiopathic focal segmental glomerulosclerosis in adults Kidney International Supplements (2012) 2, 181 185; doi:10.1038/kisup.2012.19
More informationEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 10-22-2015 Effect of mycophenolate mofetil on the white blood cell count and the frequency
More informationFOR PUBLIC CONSULTATION ONLY. Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4-RD)
Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4-RD) NHS England FOR PUBLIC CONSULTATION ONLY Evidence Review: Rituximab for immunoglobulin G4-related disease (IgG4- RD) First published:
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationKerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009
Kerry Cooper M.D. Arizona Kidney Disease and Hypertension Center April 30, 2009 DR. KERRY COOPER IS ON THE SPEAKER BUREAU OF AMGEN, ABBOTT, GENZYME, SHIRE, AND BMS DR. COOPER IS ALSO INVOLVED IN CLINICAL
More informationAtypical IgA Nephropathy
Atypical IgA Nephropathy Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA XXXIII Chilean Congress of Nephrology, Hypertension and Transplantation Puerto Varas, Chile October 6, 2016 IgA
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationWillcocks et al.,
ONLINE SUPPLEMENTAL MATERIAL Willcocks et al., http://www.jem.org/cgi/content/full/jem.20072413/dc1 Supplemental materials and methods SLE and AASV cohorts The UK SLE cohort (n = 171) was obtained from
More informationNephrotic Syndrome NS
Nephrotic Syndrome NS By : Dr. Iman.M. Mudawi Pediatric Nephrology Unit Gaafar Ibn Auf Hospital Definitions: In children NS is applied to any condition with a triad of: Heavy proteinuria (UACR ratio >200
More informationSevere lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months
Nephrol Dial Transplant (2013) 28: 2313 2318 doi: 10.1093/ndt/gft201 Advance Access publication 19 June 2013 Severe lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months Stephen
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationIRACON Management of Lupus Nephritis: Old is gold, New is Trendy
IRACON 2016 Management of Lupus Nephritis: Old is gold, New is Trendy First episode of LN (III/IV): Induction Low dose is equally considerable as high dose CYC Switch to the other agent if no improvement
More informationManagement and Outcome of Steroid-Resistant Nephrotic Syndrome in Children
kidney diseases Management and Outcome of Steroid-Resistant Nephrotic Syndrome in Children Hasan Otukesh, 1 Salman Otukesh, 2 Mona Mojtahedzadeh, 2 Rozita Hoseini, 1 Seyed-Mohammad Fereshtehnejad, 2 Azam
More informationClinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults
Clinical Commissioning Policy: Rituximab for the treatment of idiopathic membranous nephropathy in adults Reference: NHS England: 16047/P NHS England INFORMATION READER BOX Directorate Medical Operations
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationRATIONALE. K Without therapy, ANCA vasculitis with GN is associated. K There is high-quality evidence for treatment with
http://www.kidney-international.org chapter 13 & 2012 KDIGO Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis Kidney International Supplements (2012) 2, 233 239; doi:10.1038/kisup.2012.26
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationSteroid Resistant Nephrotic Syndrome. Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta
Steroid Resistant Nephrotic Syndrome Sanjeev Gulati, Debashish Sengupta, Raj K. Sharma, Ajay Sharma, Ramesh K. Gupta*, Uttam Singh** and Amit Gupta From the Departments of Nephrology, Pathology* and Biostatistics**,
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment
Specific management of IgA nephropathy: role of triple therapy and cytotoxic therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Triple therapy with cyclophosphamide,
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationResearch Article Clinicopathological Correlation in Asian Patients with Biopsy-Proven Lupus Nephritis
International Nephrology Volume 2015, Article ID 857316, 6 pages http://dx.doi.org/10.1155/2015/857316 Research Article Clinicopathological Correlation in Asian Patients with Biopsy-Proven Lupus Nephritis
More informationNephrology Grand Rounds. Mansi Mehta November 24, 2015
Nephrology Grand Rounds Mansi Mehta November 24, 2015 Case 51yo F with PMH significant for Hypertension referred to renal clinic for evaluation of elevated Cr. no known history of CKD; baseline creatinine
More informationSCI.RWDSING GLOXERULONEPHRITIS (FSGN) OF CHILDHOOD. Jerry XcCauley, X.D. Andreas G. Tzakis, X.D. John J. Fung, X.D., Ph.D. satoru Todo, M.D.
~TEKEHT WITH FK 506 OF STEROID RESISTENT FOCAL /106 SCI.RWDSING GLOXERULONEPHRITIS (FSGN) OF CHILDHOOD Jerry XcCauley, X.D. Andreas G. Tzakis, X.D. John J. Fung, X.D., Ph.D. satoru Todo, M.D. Thomas E.
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Membranous nephropathy Role of alkylating agents GUIDELINES
Membranous nephropathy Role of alkylating agents Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. Treatment with alkylating agents is associated with an increased
More informationChapter 12: Lupus nephritis Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org chapter 12 & 2012 KDIGO Chapter 12: Lupus nephritis Kidney International Supplements (2012) 2, 221 232; doi:10.1038/kisup.2012.25 INTRODUCTION This chapter makes treatment
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationReview Article. Cyclophosphamide in Lupus Nephritis. Introduction. Mechanisms of Action of CYC. Chi-Chiu Mok
Review Article Cyclophosphamide in Lupus Nephritis Chi-Chiu Mok Abstract: Keywords: Cyclophosphamide (CYC) remains the initial treatment of choice for severe lupus nephritis. However, the optimal route,
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationGlomerular Pathology- 1 Nephrotic Syndrome. Dr. Nisreen Abu Shahin
Glomerular Pathology- 1 Nephrotic Syndrome Dr. Nisreen Abu Shahin The Nephrotic Syndrome a clinical complex resulting from glomerular disease & includes the following: (1) massive proteinuria (3.5 gm /day
More informationSecondary IgA Nephropathy & HSP
Secondary IgA Nephropathy & HSP Anjali Gupta, MD 1/11/11 AKI sec to Hematuria? 65 cases of ARF after an episode of macroscopic hematuria have been reported in the literature in patients with GN. The main
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationPotential Rebalancing of the Immune System by Anti-CD52 Therapy
Potential Rebalancing of the Immune System by Anti-CD52 Therapy Johanne Kaplan, PhD VP Neuroimmunology Research Genzyme March 26, 2013 RESTRICTED USE SEE TRAINING MEMO 2011 DO Genzyme NOT 1COPY Corporation
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT HISTOPATHOLOGIC DISORDERS AFFECTING THE ALLOGRAFT OTHER THAN REJECTION RECURRENT DISEASE DE NOVO DISEASE TRANSPLANT GLOMERULOPATHY Glomerular Non-glomerular
More informationOutcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
Sigdel et al. BMC Nephrology (2016) 17:145 DOI 10.1186/s12882-016-0361-0 RESEARCH ARTICLE Open Access Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center
More informationIgA Nephropathy - «Maladie de Berger»
IgA Nephropathy - «Maladie de Berger» B. Vogt, Division de Néphrologie/Consultation d Hypertension CHUV, Lausanne 2011 Montreux CME SGN-SSN IgA Nephropathy 1. Introduction 2. Etiology and Pathogenesis
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER
European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/381922/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER The Paediatric Working Party
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationjournal of medicine The new england Sequential Therapies for Proliferative Lupus Nephritis abstract
The new england journal of medicine established in 8 march 4, 004 vol. 350 no. 0 Sequential Therapies for Proliferative Lupus Nephritis Gabriel Contreras, M.D., M.P.H., Victoriano Pardo, M.D., Baudouin
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More informationORIGINAL ARTICLE. Statistical tools used: Statistical tools used were Kappa coefficient, fisher test and odds ratio.
SIGNIFICANCE OF ACTIVITY AND CHRONICITY INDICES OF LUPUS NEPHRITIS ON RENAL OUTCOME WITH EMPHASIS ON REPEATABILITY - EXPERIENCE FROM SOUTHINDIA Seema H.S 1, Isha Garg 2, Priya Alexander 3 HOW TO CITE THIS
More informationRenal Pathology 1: Glomerulus. With many thanks to Elizabeth Angus PhD for EM photographs
Renal Pathology 1: Glomerulus With many thanks to Elizabeth Angus PhD for EM photographs Anatomy of the Kidney http://www.yalemedicalgroup.org/stw/page.asp?pageid=stw028980 The Nephron http://www.beltina.org/health-dictionary/nephron-function-kidney-definition.html
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of tonsillectomy GUIDELINES
Specific management of IgA nephropathy: role of tonsillectomy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES No recommendation possible based on Level I or II
More informationCase # 2 3/27/2017. Disclosure of Relevant Financial Relationships. Clinical history. Clinical history. Laboratory findings
Case # 2 Christopher Larsen, MD Arkana Laboratories Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationAAM Case Discussion Guide Key Learning Objectives
AAM Case Discussion Guide Key Learning Objectives List the differential diagnosis for a systemic disease presentation in a young person. Discuss the key elements of diagnosing systemic lupus erythematosus
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationManaging Acute Medical Problems, Birmingham Vasculitis. David Jayne. University of Cambridge
Managing Acute Medical Problems, Birmingham 2016 Vasculitis David Jayne University of Cambridge Disclosures Astra Zeneca, Aurinia, BIOGEN, Boehringer, Chemocentryx, Genzyme/Sanofi, GSK, Lilly, Medimmune,
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationDRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)
Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be
More informationManagement and treatment of glomerular diseases KDIGO Controversies Conference Part 1
Management and treatment of glomerular diseases KDIGO Controversies Conference Part 1 Dr.M.Matinfar Assistant Professor of Internal Medicine & Nephrology IUMS -IKRC GENERAL PRINCIPLES IN THE MANAGEMENT
More informationOut of date SUGGESTIONS FOR CLINICAL CARE (Suggestions are based on level III and IV evidence)
Membranous nephropathy role of cyclosporine therapy Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES a. The use of cyclosporine therapy alone to prevent progressive
More informationTherapy for patients with life-threatening systemic
Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis A Randomized, Controlled Trial Mark F. Gourley, MD; Howard A. Austin III, MD; Dorothy Scott, MD; Cheryl
More informationMembranous nephropathy. By Mohammed Kamal Nassar, MD Lecturer of Nephrology Mansoura University
Membranous nephropathy By Mohammed Kamal Nassar, MD Lecturer of Nephrology Mansoura University Membranous nephropathy Definition: Immune complex glomerular disease in which immune deposits of IgG and complement
More informationOlder patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective study
Manno et al. BMC Nephrology (2015) 16:88 DOI 10.1186/s12882-015-0082-9 RESEARCH ARTICLE Open Access Older patients with ANCA-associated vasculitis and dialysis dependent renal failure: a retrospective
More informationNephrotic syndrome in children. Bashir Admani KPA Nephrology Precongress 24/4/2018
Nephrotic syndrome in children Bashir Admani KPA Nephrology Precongress 24/4/2018 What is Nephrotic syndrome?? Nephrotic syndrome is caused by renal diseases that increase the permeability across the glomerular
More informationLupus Nephritis New (?) Treatments. Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris
Lupus Nephritis New (?) Treatments Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris Introduction Lupus nephritis : 30-50% of patients with lupus = mortality risk factor Mok Series
More informationPathology of Complement Mediated Renal Disease
Pathology of Complement Mediated Renal Disease Mariam Priya Alexander, MD Associate Professor of Pathology GN Symposium Hong Kong Society of Nephrology July 8 th, 2017 2017 MFMER slide-1 The complement
More informationNIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 July 14.
NIH Public Access Author Manuscript Published in final edited form as: Transplant Proc. 1990 February ; 22(1): 17 20. The Effects of FK 506 on Renal Function After Liver Transplantation J. McCauley, J.
More informationCHAPTER 3 SECONDARY GLOMERULONEPHRITIS
CHAPTER 3 SECONDARY GLOMERULONEPHRITIS Leong Chong Men Kok Lai Sun Rosnawati Yahya 53 5th Report of the 3.1: Introduction This chapter covers the main secondary glomerulonephritis that were reported to
More informationDRAFT. AAM Case Discussion Guide. Key Learning Objectives
AAM Case Discussion Guide Key Learning Objectives List the differential diagnosis for a systemic disease presentation in a young person Discuss the key elements of diagnosing systemic lupus erythematosus
More informationKey words : herpes zoster, skin reaction, systemic lunus erythematosus (SLE)
Key words : herpes zoster, skin reaction, systemic lunus erythematosus (SLE) Fig. 1 Cumulative percent of cases with herpes zoster in relation to systemic lupus eryth- (SLE). Patients with SLE who had
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More informationLupus as a risk factor for cardiovascular disease
Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Autoimmune Diseases File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_autoimmune_diseases
More informationIgA-Nephropathy: an update on treatment Jürgen Floege
IgA-Nephropathy: an update on treatment Jürgen Floege Division of Nephrology & Immunology juergen.floege@rwth-aachen.de Floege & Feehally, Nat Rev Nephrol 2013 Floege & Eitner, J Am Soc Nephrol. 2011 If
More informationSystemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience
Systemic Lupus Erythematosus among Jordanians: A Single Rheumatology Unit Experience Ala M. AlHeresh MD* ABSTRACT Objectives: To study the characteristics of Systemic Lupus Erythematosus in Jordan and
More information